Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
Omicron
SARS-CoV-2
infectiousness
vaccine-immunity
viral culture
viral shedding
Journal
Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
pubmed:
14
9
2022
medline:
28
10
2022
entrez:
13
9
2022
Statut:
ppublish
Résumé
Omicron variant is circulating in the presence of a globally acquired immunity unlike the ancestral SARS-CoV-2 isolate. Herein, we investigated the normalized viral load dynamics and viral culture status in 44 fully vaccinated healthcare workers (HCWs) infected with the Omicron BA.1 variant. Viral load dynamics of 38 unvaccinated HCWs infected with the 20A variant during the first pandemic wave was also studied. We then explored the impact of Omicron infection on pre-existing immunity assessing anti-RBD IgG levels, neutralizing antibody titres against 19A, Delta and Omicron isolates, as well as IFN-γ release following cell stimulation with SARS-CoV-2 peptides. We reported that two weeks after diagnosis a greater proportion of HCWs infected with 20A (78.9%, 15/19) than with Omicron BA.1 (44.7%, 17/38; p = 0.02) were still positive by RT-qPCR. We found that Omicron breakthrough infections led to an overall enhancement of vaccine-induced humoral and cellular immunity as soon as a median [interquartile range] of 8 [7-9] days post symptom onset. Among samples with similar high viral loads, non-culturable samples exhibited higher neutralizing antibody titres and anti-RBD IgG levels than culturable samples. Additionally, Omicron infection led to an enhancement of antibodies neutralization capacity against other SARS-CoV-2 isolates. Taken together, the results suggest that Omicron BA.1 vaccine breakthrough infection is associated with a faster viral clearance than that of the ancestral SARS-CoV-2, in addition this new variant leads to a rapid enhancement of the humoral response against multiple SARS-CoV-2 variants, and of the cellular response.
Identifiants
pubmed: 36098494
doi: 10.1080/22221751.2022.2122578
pmc: PMC9621261
doi:
Substances chimiques
Antibodies, Viral
0
Viral Vaccines
0
Immunoglobulin G
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2423-2432Références
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Nature. 2022 Jul;607(7918):356-359
pubmed: 35523247
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
J Travel Med. 2022 May 31;29(3):
pubmed: 35262737
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Clin Chem. 2021 Apr 29;67(5):742-752
pubmed: 33399823
N Engl J Med. 2022 Jul 21;387(3):275-277
pubmed: 35767428
BMJ. 2020 Oct 23;371:m3862
pubmed: 33097561
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
Clin Infect Dis. 2021 Jun 1;72(11):e921
pubmed: 32986798
Eur J Immunol. 2021 Dec;51(12):3239-3242
pubmed: 34387859
Sci Rep. 2021 Jul 22;11(1):14977
pubmed: 34294751
JAMA Netw Open. 2022 May 2;5(5):e2213606
pubmed: 35608859
Nat Commun. 2022 Oct 23;13(1):6316
pubmed: 36274062
BMJ Open. 2020 Nov 24;10(11):e041268
pubmed: 33234651
Clin Microbiol Infect. 2020 Jul;26(7):960-962
pubmed: 32234449
Nat Med. 2022 Jul;28(7):1491-1500
pubmed: 35395151